Remdesivir of Gilead accelerates COVID-19 recovery
Gilead Sciences' Remdesivir shows the first data from a placebo-controlled study. Remdesivir decreases recovery time for hospitalized COVID-19 patients by four days or 31% as published in a National Institutes of Health-sponsored study setting the drug against placebo in more than thousands of patients.
The Food and Drug Administration (FDA) could give the nod to remdesivir for emergency use according to the results.
The study had carried out at 68 sites around the world, recovery as being healthy to return normal activity level. The trial was not reserved for the sickest of patients, not like other trials th...
